DRUG NAME: Torasemide

---

Therapeutic Class:

---

Subclass:

---

Schedule (India):

---

Route(s)

• Oral (tablets — immediate release)
• IV (slow bolus or continuous infusion)

---

Biosimilar Status:

---

Formulations Available in India

---

PHARMACOKINETICS

---

1. Threshold dose: A minimum drug concentration must be achieved in the tubular lumen to inhibit NKCC2 and initiate natriuresis. Below this threshold, no clinically meaningful diuresis occurs. Unlike a linear dose-response, increasing the dose from sub-threshold to threshold produces a dramatic (“all-or-none”) change in response.
2. Ceiling dose: Once all luminal NKCC2 transporters are maximally inhibited, further dose increases produce no additional natriuresis — only increased risk of adverse effects (electrolyte depletion, ototoxicity, metabolic derangements). Approximate ceiling doses:
   • Torasemide: 200 mg (single dose, oral or IV)
   • Furosemide: 400 mg (single dose)
   • In advanced CKD (eGFR <15): ceiling may be reached at even higher doses, but the absolute natriuretic response is still reduced.
3. Rightward shift in disease states: In heart failure, CKD, nephrotic syndrome, and cirrhosis, the dose-response curve shifts rightward — higher doses are required for the same effect due to:
   • Reduced renal blood flow → less drug delivery
   • OAT competition from uraemic toxins (CKD)
   • Intraluminal albumin binding of torasemide (nephrotic syndrome)
   • Compensatory upregulation of distal nephron sodium reabsorption
4. Torasemide’s longer duration advantage: Furosemide’s shorter action (4–6 hours) creates a drug-free interval during which compensatory sodium retention occurs (“diuretic braking”). Torasemide’s 6–8-hour duration reduces this phenomenon, contributing to more effective and smoother diuresis. This translates to fewer episodes of post-diuresis rebound oedema and potentially better symptom control.

---

---

Population Pharmacokinetic Notes:

---

• The TRANSFORM-HF trial (2022, JAMA — pragmatic RCT, n=2,859) comparing torasemide to furosemide in heart failure patients found no significant difference in all-cause mortality at 12 months.
• Therefore, while this pharmacological property is of academic interest and may contribute to soft endpoints, it has not translated into a mortality benefit in the largest comparative trial to date.
• Torasemide’s advantages over furosemide remain primarily pharmacokinetic (bioavailability, duration of action, predictability) rather than based on this anti-fibrotic property.

---

ADULT INDICATIONS + DOSING

---

KEY LOOP DIURETIC PRESCRIBING PRINCIPLES

---

DIURETIC RESISTANCE MANAGEMENT PROTOCOL

---

Primary Indication 1: ACUTE DECOMPENSATED HEART FAILURE (ADHF) — Decongestive Therapy

---

---

1. When to prefer torasemide over alternatives:
   • (a) Advantage over furosemide: (i) More predictable oral bioavailability (~80–90% vs ~50%, range 10–100%), which is practically significant when transitioning from IV to oral — the most error-prone moment in ADHF management. (ii) Longer duration of action (6–8 hours vs 4–6 hours) → less post-dose rebound sodium retention → more consistent 24-hour sodium excretion. (iii) 1:1 oral-to-IV dose ratio simplifies route transitions (vs 2:1 for furosemide). (iv) Unique anti-aldosterone and anti-fibrotic properties (see Unique Pharmacological Note in PK section, Part 1 — cross-reference only, not repeated here).
   • (a) Advantage over bumetanide: Similar oral bioavailability (~80%), but torasemide has a longer half-life (3–4 hours vs 1–1.5 hours) and correspondingly longer duration of diuretic action. Bumetanide is less commonly available in India.
   • (b) Torasemide is an acceptable first-line loop diuretic for ADHF. CSI Heart Failure Guidelines and API Textbook recognise both furosemide and torasemide as first-line loop diuretics. Torasemide is NOT established as categorically “superior” — the TRANSFORM-HF trial (2022, JAMA, n=2,859) showed no mortality difference vs furosemide. Its advantages are pharmacokinetic (bioavailability, predictability, duration), not outcome-based.
   • © Compared against: Furosemide (most commonly used in Indian practice, NLEM-listed, cheapest), bumetanide (limited availability in India, not widely stocked).
   • Honest assessment: Switching a furosemide-responding patient to torasemide is NOT necessary for outcomes. Consider switching when: (i) variable oral furosemide absorption is suspected (escalating oral doses with inconsistent response), (ii) simpler IV-to-oral transition is desired, (iii) once-daily dosing preferred for adherence (furosemide often requires BD in chronic HF), (iv) furosemide not tolerated.
2. When NOT to use:
   • ⛔ Anuric patient (no renal urine formation — loop diuretic has no target).
   • ⛔ Severe uncorrected hypovolaemia / dehydration (worsens pre-renal AKI).
   • ⛔ Hypertrophic obstructive cardiomyopathy (HOCM) with significant outflow tract gradient — volume depletion worsens dynamic obstruction. Use diuretics very cautiously and only under cardiologist guidance.
   • ⛔ Severe hyponatraemia (Na⁺ <125 mEq/L) without specialist oversight — loop diuretics can worsen hyponatraemia in certain contexts (though in hypervolaemic hyponatraemia of HF, loop diuretics with free water restriction are appropriate under monitoring).
   • ⛔ Known hypersensitivity to torasemide or sulfonamide-derived drugs (see Contraindications, Part 4).
3. NLEM India status: ⚠️ Torasemide is NOT listed in NLEM India 2022. Furosemide is the NLEM-listed loop diuretic (tablets 20 mg, 40 mg; injection 10 mg/mL). Furosemide is available in government hospitals, PHCs, and PMBJP stores. In government/resource-limited settings, furosemide remains the default choice.
4. Time to expected clinical response:
   • IV bolus: Diuretic effect within 10 minutes; peak urine output at ~1 hour. Expect measurable clinical improvement (reduced dyspnoea, decreasing weight) within 6–12 hours of adequate IV dosing.
   • Oral: Diuretic effect within 30–60 minutes; peak at 1–2 hours. Weight reduction of 0.5–1 kg/day expected with adequate dosing and sodium restriction.
   • ℹ️ If no significant urine output increase within 2 hours of IV bolus → dose is below the threshold. Double the dose and reassess.
5. Criteria for treatment failure: Persistent or worsening congestion (weight gain, rising JVP, increasing dyspnoea) despite ceiling-dose torasemide (200 mg/day). Action: Follow the Diuretic Resistance Management Protocol (above). Specifically: (a) Confirm sodium restriction compliance (spot urine Na⁺). (b) Add sequential nephron blockade (metolazone). © Switch to continuous IV infusion. (d) Evaluate for cardiorenal syndrome. (e) Consider ultrafiltration.
6. Mandatory baseline investigations:
   • MANDATORY: Serum electrolytes (Na⁺, K⁺, Cl⁻, Mg²⁺), serum creatinine / eGFR, blood urea, baseline body weight, BP (supine and standing if feasible), urine output assessment (catheterise in ICU if needed for accurate measurement).
   • RECOMMENDED: BNP or NT-proBNP (for diagnostic confirmation and trending), CBP, LFT, serum uric acid, random blood glucose, ECG (baseline rhythm, QTc — hypokalaemia from diuretics can prolong QTc), chest X-ray, echocardiography (if not done recently).
7. Specialist initiation: ADHF requiring IV diuretic therapy: typically managed by cardiologist or internal medicine physician in emergency/ICU setting. Can be initiated by trained emergency medicine physicians. ⚠️ Primary care initiation of IV diuretics is not recommended — refer to higher centre.
8. Indian guideline source: CSI (Cardiological Society of India) Heart Failure Management Guidelines (2018 / 2022 update); API Textbook of Medicine — Heart Failure chapter; ESC Heart Failure Guidelines (2021/2023) as adapted in Indian tertiary centre protocols (AIIMS, PGIMER, SCTIMST).
9. Key disease-specific safety warning: ⚠️ “Pseudo-Worsening Renal Function” (WRF) during decongestion: A modest rise in serum creatinine (0.3–0.5 mg/dL) during active diuresis in ADHF is common and does NOT necessarily indicate harm. This is often haemoconcentration-related “pseudo-WRF” reflecting successful intravascular volume reduction. It may also reflect improved renal venous decongestion (paradoxically beneficial long-term). ⛔ Do NOT reflexively discontinue torasemide for a modest creatinine rise if the patient is clinically improving (reducing congestion, declining weight, improving symptoms). Concern is warranted when: creatinine rises >0.5 mg/dL, oliguria develops (<0.5 mL/kg/h for >6 hours), or clinical improvement is absent despite rising creatinine. Consult cardiology/nephrology in such cases.
10. Common scenarios requiring dose adjustment:
    • Concurrent ACEi/ARB/ARNI initiation: May improve diuretic efficacy → reduce torasemide dose by 25–50% to avoid over-diuresis. Monitor creatinine and K⁺ within 48–72 hours.
    • ⚠️ Concurrent SGLT2 inhibitor initiation (dapagliflozin/empagliflozin): Additive natriuretic and diuretic effect. When initiating SGLT2i in a patient already on torasemide: reduce torasemide dose by 25–50% or monitor closely for over-diuresis. Under-recognition of this additive effect is an increasingly common prescribing error in India as SGLT2i use in HF expands (DAPA-HF, EMPEROR-Reduced evidence).
    • Acute illness with vomiting/diarrhoea: Hold or reduce torasemide temporarily to prevent dehydration and AKI.
    • Post-discharge: Patients often need lower diuretic doses than inpatient doses — reassess within 1–2 weeks post-discharge. Many readmissions are due to either over-diuresis (AKI, hypotension) or under-diuresis (recurrent congestion) from failure to adjust the outpatient dose.
    • Indian summer months (April–June): Increased insensible losses from sweating compound diuretic-induced volume depletion → higher AKI and dehydration risk. Counsel patients to weigh daily and report reduced urine output or dizziness.
11. Common investigation misconception flag: ℹ️ BNP/NT-proBNP should NOT be used as the sole guide for diuretic dose titration. BNP levels correlate with ventricular wall stress and may remain elevated despite adequate decongestion (especially in HFpEF, renal impairment, atrial fibrillation, and obesity). Use clinical assessment (weight, JVP, lung auscultation, peripheral oedema, urine output) as the PRIMARY guide. BNP trending is a SUPPORTIVE adjunct, not the primary dose-adjustment criterion.
12. Dose escalation rationale: In ADHF patients with concurrent CKD (eGFR <30 mL/min), higher torasemide doses (50–200 mg) may be needed to achieve diuretic threshold concentrations at the tubular lumen. This dose escalation is for efficacy (overcoming reduced OAT-mediated drug delivery to the luminal NKCC2 target due to uraemic organic anion competition), NOT for safety/toxicity avoidance. Torasemide does not accumulate to systemically toxic levels because ~80% of its clearance is hepatic, not renal. Do NOT reflexively reduce the torasemide dose in CKD — this leads to therapeutic failure (persistent congestion).

---

Primary Indication 2: CHRONIC HEART FAILURE — Maintenance Diuresis

---

1. When to prefer torasemide over alternatives:
   • (a) Advantage over furosemide for chronic oral maintenance: (i) Once-daily dosing with smoother diuretic profile. Furosemide’s shorter action (4–6 hours) creates a “sine wave” pattern: intense diuresis followed by a prolonged drug-free interval during which the kidney avidly reabsorbs sodium (post-diuretic sodium retention / diuretic braking). Torasemide’s 6–8 hour action reduces this rebound. (ii) Furosemide often requires BD dosing for adequate chronic control, reducing adherence. (iii) Torasemide’s more predictable oral bioavailability (~80–90% vs furosemide’s ~50%) provides more consistent diuresis day-to-day.
   • (b) Torasemide is a reasonable first-line or switch option for chronic HF diuresis. Not categorically superior to furosemide in mortality outcomes (TRANSFORM-HF trial), but pharmacokinetically more predictable.
   • © Compared against: Furosemide (most commonly used, NLEM-listed, cheapest), bumetanide (limited Indian availability).
   • Practical Indian scenario where switching to torasemide is most justified: (i) Patient requires unpredictable dose escalation of oral furosemide, suggesting variable absorption. (ii) Patient requires BD furosemide and adherence is problematic — torasemide OD may improve adherence. (iii) Patient has persistent rebound oedema in the evening despite adequate morning furosemide dosing. (iv) IV-to-oral transition (torasemide’s 1:1 ratio is simpler).
2. When NOT to use: Same as ADHF — anuria, severe uncorrected hypovolaemia, HOCM with significant obstruction. Additionally: do not prescribe torasemide for chronic maintenance in patients whose HF is well-controlled on furosemide with no adherence or absorption concerns — switching for the sake of switching is not evidence-based.
3. NLEM India status: NOT NLEM. Furosemide is the NLEM-listed loop diuretic for chronic HF. In government hospitals and resource-limited settings, furosemide is the pragmatic first choice.
4. Time to expected clinical response: Stable weight and symptom control typically achieved within 1–2 weeks of appropriate dose titration with sodium restriction. If no improvement after 2 weeks of adequate dosing + verified sodium compliance: reassess diagnosis, evaluate for diuretic resistance.
5. Criteria for treatment failure: Progressive fluid retention despite adequate dose + sodium restriction. Weight gain >1 kg/week. Worsening NYHA class. Repeated ADHF hospitalisations. Action: (a) Add spironolactone/eplerenone if not already on MRA — mortality benefit in HFrEF (RALES, EMPHASIS-HF). (b) Add sequential nephron blockade (metolazone). © Reassess optimisation of neurohormonal blockade (ACEi/ARB/ARNI, beta-blocker, SGLT2i). (d) Consider advanced HF therapies.
6. Mandatory baseline investigations: MANDATORY: Serum electrolytes (K⁺, Na⁺, Mg²⁺), serum creatinine / eGFR, body weight. RECOMMENDED: BNP/NT-proBNP, echocardiography (if not done in past 12 months), serum uric acid, fasting glucose, LFT.
7. Specialist initiation: Initial HF diagnosis and treatment: cardiologist or trained internal medicine physician. Chronic maintenance dose adjustments: can be managed by trained primary care physician with periodic cardiologist review (every 3–6 months if stable). ℹ️ Patient-directed flexible dosing (“take an extra 10 mg if your weight goes up by >1 kg over 2 days; reduce by 10 mg if you feel dizzy or notice very low urine output”) can improve self-management. Implement only in patients who can reliably weigh themselves daily and understand the instructions. Requires adequate patient education — provide a simple written action plan.
8. Indian guideline source: CSI Heart Failure Guidelines; API Textbook of Medicine — Heart Failure chapter; adapted ESC HF Guidelines used at AIIMS, PGIMER, CMC Vellore.
9. Key disease-specific safety warning: ⚠️ SGLT2 inhibitor co-prescribing (see item 10 under ADHF). ⚠️ Potassium monitoring: When torasemide is combined with an MRA (spironolactone/eplerenone) — standard HF therapy — the net potassium effect depends on the balance of kaliuretic (torasemide) and potassium-sparing (MRA) forces. Monitor K⁺ within 1 week of initiation/dose change and at least monthly thereafter. Maintain K⁺ ≥4.0 mEq/L in HF patients (hypokalaemia + HF + digoxin = dangerous arrhythmia risk).
10. Common scenarios requiring dose adjustment: Same as ADHF (SGLT2i initiation, ACEi/ARB/ARNI initiation, inter-current illness, hot weather). Additionally: post-cardiac surgery (diuretic requirements often change significantly — reassess).
11. Common investigation misconception flag: ℹ️ Serum creatinine alone does NOT reflect diuretic adequacy. A patient with “normal” creatinine may be significantly congested (under-diuresed). Conversely, a modest creatinine rise (0.3 mg/dL) with clinical improvement (weight loss, reduced oedema) does not indicate diuretic harm. Use clinical assessment (weight, JVP, oedema, lung auscultation) as primary efficacy markers, not creatinine alone.
12. Dose escalation rationale: In chronic HF patients with concurrent CKD: higher doses are for efficacy (overcoming rightward shift of dose-response curve), not toxicity avoidance. See ADHF item 12. Additionally, in patients with very high urinary albumin excretion (concurrent nephrotic-range proteinuria): intraluminal albumin binding of torasemide further shifts the curve rightward, requiring higher doses.

---

Primary Indication 3: OEDEMA ASSOCIATED WITH RENAL DISEASE (Chronic Kidney Disease, Nephrotic Syndrome)

---

• Higher bolus doses (overcome binding by mass action)
• Continuous IV infusion (sustain luminal concentration above threshold despite binding)
• Sequential nephron blockade: Metolazone 2.5–5 mg orally 30 minutes before torasemide. ⚠️ Monitor electrolytes Q6–12h when using this combination — profound hypokalaemia and hyponatraemia can develop within 24–48 hours.
• Albumin co-infusion: IV albumin 20% (0.5–1 g/kg over 30 minutes) immediately before IV torasemide bolus. Rationale: transient increase in plasma albumin improves OAT-mediated drug delivery. API Textbook notes this as a therapeutic option. Evidence is mixed but widely practised at AIIMS and PGIMER nephrology departments.

---

1. When to prefer torasemide over alternatives:
   • (a) Advantage over furosemide in CKD: More predictable oral absorption — particularly valuable in CKD patients with GI oedema or diabetic gastroparesis (common in diabetic CKD, which constitutes the majority of CKD in India per ICMR data). 1:1 oral-to-IV ratio simplifies transitions. Longer duration reduces rebound sodium retention.
   • (b) Acceptable alternative first-line loop diuretic for CKD oedema. Furosemide remains most widely used and NLEM-listed.
   • © Compared against: Furosemide (NLEM, cheapest, most widely available), bumetanide (limited Indian availability).
   • No specific advantage over furosemide in CKD outcomes. Consider torasemide when: oral furosemide absorption is suspected to be unreliable, adherence with BD furosemide is problematic, or IV-to-oral transition is needed.
2. When NOT to use: Anuric patients (eGFR <5 mL/min with no residual urine output — loop diuretics are futile). Pre-renal AKI with hypovolaemia (correct volume first). Severe uncorrected electrolyte derangements (K⁺ <3.0 mEq/L, Na⁺ <120 mEq/L) — correct before initiating or escalating diuretics.
3. NLEM India status: NOT NLEM. Furosemide is NLEM-listed.
4. Time to expected clinical response: Diuretic onset per route (as above). Weight loss of 0.5–1 kg/day expected. If no weight loss after 48–72 hours of adequate dosing: evaluate for diuretic resistance per the Protocol above.
5. Criteria for treatment failure: No meaningful diuresis at ceiling dose (200 mg/day) despite sodium restriction. Action: Sequential nephron blockade (metolazone), IV route, albumin co-infusion (nephrotic), dialysis/ultrafiltration referral.
6. Mandatory baseline investigations: MANDATORY: Serum electrolytes (K⁺, Na⁺, Mg²⁺, Ca²⁺), serum creatinine / eGFR, body weight, urine output monitoring. RECOMMENDED: Spot urine Na⁺ (to assess sodium restriction compliance — urine Na⁺ >100 mEq/L suggests dietary non-compliance), serum albumin, serum uric acid, urine protein/creatinine ratio or 24-hour urine protein.
7. Specialist initiation: CKD stages 1–3 with mild oedema: trained primary care physician can manage. CKD stages 4–5 and nephrotic syndrome: nephrology specialist.
8. Indian guideline source: Indian Society of Nephrology (ISN-India) CKD management guidelines; API Textbook of Medicine — CKD and Nephrotic Syndrome chapters; AIIMS nephrology protocols.
9. Key disease-specific safety warning: ⚠️ Torasemide can mask declining renal function: Adequate urine output from loop diuretic may give false reassurance while eGFR is actually declining. Monitor creatinine/eGFR regularly — do NOT rely on urine output alone. ⚠️ Gout exacerbation risk: Torasemide increases proximal tubular uric acid reabsorption (competition for OAT-mediated secretion). CKD patients already have elevated uric acid → loop diuretics can precipitate acute gout, which is common in Indian CKD patients. Monitor serum uric acid periodically and treat/prophylax as needed.
10. Common scenarios requiring dose adjustment: ACEi/ARB initiation (recheck electrolytes and creatinine within 1–2 weeks). SGLT2i initiation (additive natriuresis — reduce torasemide by 25–50%). Inter-current illness with reduced oral intake (hold diuretic temporarily). Dialysis initiation (loop diuretics usually discontinued once anuric; may be continued for residual renal function in early dialysis).
11. Common investigation misconception flag: ℹ️ Spot urine sodium is more clinically useful than 24-hour urine sodium for quick outpatient assessment of dietary compliance. Urine Na⁺ <50 mEq/L suggests reasonable sodium restriction. Urine Na⁺ >100 mEq/L strongly suggests dietary sodium excess — the most common cause of apparent “diuretic resistance.”
12. Dose escalation rationale: ⚠️ This is the most critical dose-escalation concept for this indication. In CKD, torasemide dose escalation is needed for efficacy, NOT for safety/toxicity avoidance. The drug does NOT accumulate to systemically toxic levels (80% hepatic clearance). Rather, reduced OAT1/OAT3-mediated tubular secretion (due to competition from accumulated uraemic organic anions — hippurate, indoxyl sulfate) delivers less drug to the luminal site of action. Higher oral/IV doses are needed to overcome this pharmacodynamic resistance and achieve threshold luminal concentrations. ⛔ Do NOT reflexively reduce torasemide dose in CKD. This is the opposite of the correct action and will result in therapeutic failure (persistent oedema, worsening congestion). Dose REDUCTION is appropriate only if the patient develops signs of over-diuresis (hypovolaemia, pre-renal AKI, hypotension).

---

Primary Indication 4: OEDEMA ASSOCIATED WITH HEPATIC CIRRHOSIS (Ascites)

---

1. When to prefer torasemide over furosemide in cirrhosis:
   • (a) Advantage: Better oral bioavailability (~80–90% vs ~50%) — relevant because cirrhotic patients often have intestinal wall oedema from portal hypertension that impairs furosemide absorption. Longer duration provides smoother natriuresis. ℹ️ Torasemide’s half-life is further prolonged in cirrhosis (7–8 hours due to reduced CYP2C9 metabolism), extending the effective diuretic window per dose.
   • (b) Acceptable alternative to furosemide. Indian hepatology practice predominantly uses furosemide (NLEM-listed, familiar). INASL guidelines (2019) mention furosemide as the standard loop diuretic for ascites but do not specifically recommend against torasemide.
   • © Compared against: Furosemide (NLEM, most commonly used), bumetanide (rarely used in India for this indication).
2. When NOT to use:
   • ⛔ Hepatic coma or pre-coma (diuretic-induced dehydration and electrolyte disturbances precipitate/worsen hepatic encephalopathy).
   • ⛔ Active gastrointestinal bleeding (volume depletion worsens haemorrhagic shock).
   • ⛔ Severe hyponatraemia (Na⁺ <120 mEq/L) — hold ALL diuretics, restrict free water.
   • ⛔ Hepatorenal syndrome (HRS) type 1 — diuretics are contraindicated; treatment is albumin + terlipressin.
   • ⛔ Active spontaneous bacterial peritonitis (SBP) — hold diuretics during SBP treatment (increased renal impairment risk). Resume after SBP resolution.
   • ⛔ Torasemide monotherapy (without spironolactone) in cirrhosis — ineffective due to overwhelming distal aldosterone-mediated sodium reabsorption.
3. NLEM India status: NOT NLEM. Furosemide and spironolactone are both NLEM-listed.
4. Time to expected clinical response: Weight loss of 0.25–0.5 kg/day (ascites only) or 0.5–1 kg/day (with peripheral oedema) over 1–2 weeks. If no response after 5–7 days: consider refractory ascites.
5. Criteria for treatment failure (Refractory ascites — INASL definition): Ascites that cannot be mobilised or recurs despite maximum diuretic therapy (torasemide 40 mg + spironolactone 400 mg) AND strict sodium restriction (<2 g/day). OR: Diuretic-induced complications (encephalopathy, renal impairment, hyponatraemia <125 mEq/L, K⁺ <3.0 or >6.0 mEq/L) precluding dose escalation. Action: Large-volume paracentesis (LVP) with albumin infusion (6–8 g albumin per litre removed beyond 5 L). TIPS in selected patients. Liver transplant evaluation.
6. Mandatory baseline investigations: MANDATORY: Serum electrolytes (K⁺, Na⁺), serum creatinine / eGFR, LFT (including serum albumin — critical for assessing protein binding and disease severity), body weight. RECOMMENDED: Diagnostic paracentesis with ascitic fluid analysis (cell count, albumin — SAAG ≥1.1 g/dL confirms portal hypertension; culture if SBP suspected), spot urine Na⁺, serum ammonia (if encephalopathy suspected).
7. Specialist initiation: Hepatologist or gastroenterologist. Stable patients on established regimen: primary care can manage with periodic specialist review.
8. Indian guideline source: INASL (Indian National Association for Study of the Liver) Guidelines on Management of Ascites in Cirrhosis (2019); API Textbook of Medicine — Cirrhosis and Ascites chapters.
9. Key disease-specific safety warning: ⚠️ Hepatic encephalopathy: Diuretic-induced hypovolaemia, hypokalaemia, and metabolic alkalosis all increase renal ammonia production and decrease hepatic ammonia clearance → precipitate/worsen hepatic encephalopathy. Monitor mental status at EVERY visit. If new confusion, asterixis, or altered sensorium: ⛔ STOP ALL diuretics immediately, check electrolytes and ammonia, hydrate, initiate lactulose ± rifaximin. Resume diuretics cautiously at lower dose only after encephalopathy resolves. ⚠️ Muscle cramps: Prevalence ~50–70% in cirrhotic patients on diuretics. Management: correct electrolytes (Mg²⁺, K⁺), consider baclofen 10 mg TDS (used at some Indian hepatology centres), albumin infusion.
10. Common scenarios requiring dose adjustment: After LVP (hold diuretics 24–48 hours, then resume at reduced dose). AKI during diuretic therapy (hold, hydrate, rule out HRS). Post-TIPS (diuretic requirements often decrease substantially — reduce doses, monitor for over-diuresis).
11. Common investigation misconception flag: ℹ️ Serum creatinine is UNRELIABLE in cirrhosis as a true GFR marker. Cirrhotics have low muscle mass (low creatinine production) and high bilirubin (Jaffé assay interference). A “normal” creatinine of 1.0 mg/dL in a cachectic cirrhotic patient may represent eGFR <30 mL/min. Use cystatin C–based eGFR if available. If unavailable: use measured 24-hour creatinine clearance or clinical judgement (urine output, fluid responsiveness).
12. Dose escalation rationale: In cirrhosis, diuretic resistance is primarily pharmacodynamic (overwhelmingly active RAAS/aldosterone axis driving distal sodium reabsorption, reduced effective circulating volume, reduced renal perfusion) rather than pharmacokinetic. Higher doses of torasemide alone are often insufficient — adding/escalating spironolactone is more effective than escalating the loop diuretic. The ceiling dose for torasemide in cirrhosis (40 mg) is lower than in CKD/HF (200 mg) because of the heightened risk of electrolyte derangement and encephalopathy in cirrhosis.

---

Primary Indication 5: HYPERTENSION

---

---

1. When to prefer torasemide over alternatives:
   • (a) Advantage: Only when thiazide diuretics are ineffective (eGFR <30), not tolerated (severe hyponatraemia, symptomatic hyperuricaemia with gout), or when concurrent fluid overload needs management. No specific advantage over thiazides for uncomplicated hypertension with eGFR >30.
   • (b) NOT first-line. Alternative agent for specific scenarios.
   • © Compared against: Chlorthalidone (preferred thiazide-type per ALLHAT data), hydrochlorothiazide, indapamide (all preferred for uncomplicated hypertension), furosemide (alternative loop diuretic — less commonly used for chronic hypertension due to BD dosing requirement and shorter duration).
2. When NOT to use: Uncomplicated hypertension with eGFR >30 and no fluid overload. Isolated systolic hypertension in elderly (CCB or thiazide preferred). Hypertensive emergency (torasemide is NOT an acute BP-lowering drug).
3. NLEM India status: NOT NLEM. Hydrochlorothiazide (NLEM-listed diuretic for hypertension). Chlorthalidone and furosemide also NLEM-listed.
4. Time to expected clinical response:4–6 weeks for full antihypertensive effect. Do NOT assess response or escalate dose before 4 weeks.
5. Criteria for treatment failure: BP not at target after 6–8 weeks on maximum antihypertensive dose (10 mg/day). Action: Add second agent (ACEi/ARB or CCB). Reassess for secondary causes of hypertension.
6. Mandatory baseline investigations: MANDATORY: BP measurement (office + home if available), serum electrolytes (K⁺, Na⁺), serum creatinine / eGFR, fasting blood glucose. RECOMMENDED: Fasting lipid profile, serum uric acid, urine routine (protein, glucose), ECG, echocardiography if LVH suspected.
7. Specialist initiation: Can be initiated by any registered medical practitioner. Specialist referral if resistant hypertension (uncontrolled on ≥3 drugs at optimal doses including a diuretic).
8. Indian guideline source: IGH-IV (Indian Guidelines on Hypertension, 4th edition, 2019); CSI/HSI recommendations; API Textbook — Hypertension chapter.
9. Key disease-specific safety warning: ⚠️ Hypokalaemia-induced arrhythmias: Torasemide-induced hypokalaemia prolongs QTc and predisposes to ventricular arrhythmias (torsades de pointes), especially with concurrent digoxin, antiarrhythmics, or other QT-prolonging drugs. Monitor K⁺ within 1–2 weeks of initiation and periodically. Maintain K⁺ ≥4.0 mEq/L in patients at arrhythmia risk.
10. Common scenarios requiring dose adjustment: ACEi/ARB initiation (additive hypotension). NSAID use (blunts antihypertensive effect — see Interactions, Part 4). Hot weather (dehydration risk). Inter-current illness with reduced oral intake.
11. Common investigation misconception flag: Not specifically applicable for the hypertension indication.
12. Dose escalation rationale: Not applicable for hypertension — doses above 10 mg/day do not provide additional BP reduction and shift the drug into diuretic mode.

---

Secondary Indications — Adults Only (Off-label)

---

Secondary Indication 1: ACUTE HYPERCALCAEMIA — Adjunct to IV Saline Hydration

• Modern hypercalcaemia management emphasises IV saline hydration and bisphosphonates (zoledronic acid 4 mg IV single dose). Loop diuretics are now considered adjunctive — used primarily to prevent volume overload from aggressive hydration or to enhance calciuresis in severe/refractory cases.
• Monitor K⁺, Mg²⁺, Na⁺, Ca²⁺ every 4–6 hours during active calciuresis.
• Zoledronic acid is available in India (NLEM-listed for malignancy-associated hypercalcaemia).

---

Secondary Indication 2: RESISTANT HYPERTENSION — Loop Diuretic Switch Strategy

• When replacing thiazide with torasemide for resistant hypertension: cross-titrate (start torasemide, then discontinue thiazide after 1–2 weeks once torasemide effect is established) to avoid BP rebound during transition.
• Monitor electrolytes closely during the switch period.

---

MISSED DOSE / DELAYED DOSE GUIDANCE

---

---

• A single missed dose does NOT cause dangerous rebound (unlike clonidine or beta-blockers).
• No re-titration is needed after a single missed dose.
• No rebound hypertension occurs upon missing a dose.

---

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE

---

IV ADMINISTRATION

• Loading dose: 20 mg IV bolus (2 mL of 10 mg/mL solution) over 2–5 minutes.
• Infusion preparation: Draw 200 mg torasemide (five 4 mL ampoules of 10 mg/mL = 20 mL) into 180 mL NS → total volume 200 mL, concentration = 1 mg/mL.
• Start infusion at 10 mL/hour = 10 mg/hour.
• Titrate upward by 5 mL/hour (5 mg/hour) increments every 2–4 hours if urine output remains below 100 mL/hour.
• Maximum: 20 mL/hour = 20 mg/hour.
• Daily total: 20 mg loading + (10 mg/hour × 24h) = 260 mg/day (specialist supervision required for doses exceeding the standard 200 mg/day ceiling in this context).

---

STABILITY AFTER DILUTION

---

Y-SITE / LINE COMPATIBILITY

---

ORAL ADMINISTRATION

---

STORAGE

---

PAEDIATRIC DOSING (Specialist Only)

---

General Notes

• Regulatory status in India: Torasemide does NOT have a specific CDSCO-approved paediatric indication or dosing recommendation. All paediatric use is OFF-LABEL.
• Standard of care: Furosemide is the established first-line loop diuretic in paediatric practice across India, endorsed by IAP guidelines and MoHFW protocols. Torasemide is NOT included in IAP drug lists, WHO EML for Children, or Indian paediatric treatment guidelines.
• Evidence base: Limited to small observational studies, case series, and pharmacokinetic extrapolation from adult data. No paediatric randomised controlled trials establish safety and efficacy of torasemide in children. Level of evidence: Weak.
• NLEM India status: Not listed for paediatric use.

• Only tablet formulations (5 mg, 10 mg, 20 mg, 40 mg, 100 mg) are marketed in India. No commercially available oral liquid, suspension, or dispersible tablet formulation exists in the Indian market.
• Tablets may be crushed and dispersed in a small volume of water (5–10 mL) for younger children unable to swallow tablets whole. However, stability and bioequivalence data for such extemporaneous preparations are lacking; use within 15 minutes of preparation.
• Palatability: Torasemide tablets have a bitter taste. If crushed, mixing with a small volume of fruit juice or honey (in children >1 year) may improve acceptance, but this is not formally studied and may not fully mask the taste.
• The 5 mg tablet is the smallest available strength. For children requiring doses <5 mg, accurate subdivision of tablets is unreliable — this limits use in young/small children.

• CYP2C9 (the primary metabolising enzyme for torasemide) is immature at birth, reaching approximately 20–30% of adult catalytic activity by 1 month of age and near-adult levels by 1–3 years.
• In neonates and young infants (<6 months), significantly reduced CYP2C9 activity results in unpredictable hepatic clearance and prolonged half-life of torasemide.
• Protein binding may be lower in neonates and infants (lower albumin concentrations, competitive displacement by bilirubin), increasing the free drug fraction and potentially amplifying both therapeutic and adverse effects.
• Renal maturation (GFR, tubular secretory function) is incomplete at birth and reaches adult-equivalent values (normalised to BSA) by approximately 1–2 years. This affects drug delivery to the tubular site of action via OAT-mediated secretion.
• Net effect in young infants: Combination of immature hepatic metabolism AND immature renal secretion makes torasemide pharmacokinetics doubly unpredictable below 1 year of age.

• Serum electrolytes (K⁺, Na⁺, Mg²⁺, Ca²⁺) — baseline and within 48–72 hours of initiation, then weekly during dose titration
• Renal function (serum creatinine, blood urea) — baseline and weekly during titration
• Daily weight and strict fluid balance charting (input/output)
• Blood pressure monitoring at every dose change (risk of hypotension, particularly in volume-depleted children)
• Growth monitoring (height, weight percentiles) for chronic use — no specific growth suppression data for torasemide, but chronic diuretic-related electrolyte derangement can impair growth
• Urine output documentation — target 1–2 mL/kg/hour in acute settings

1. Poor or erratic oral absorption of furosemide (furosemide oral bioavailability ~40–60%, highly variable, vs torasemide ~80%, more consistent) — relevant when transitioning a stable child from IV to oral diuretic and consistent oral diuresis is needed
2. Documented furosemide hypersensitivity (⚠️ cross-reactivity between loop diuretics containing sulfonamide moiety is possible — see Contraindications in Part 4)
3. Clinical suspicion of excessive post-diuretic rebound sodium retention with furosemide (torasemide’s longer duration of action may theoretically reduce this, though paediatric evidence is absent)

---

Neonatal Dosing

• “Based on extrapolation from limited adult pharmacokinetic data and CYP2C9 ontogeny principles; no validated neonatal dosing regimen exists.”
• NICU supervision only — continuous cardiorespiratory monitoring, strict intake/output, daily electrolytes
• This is an exceptional/last-resort option, NOT a preferred agent
• Onset of action following oral administration in neonates is unpredictable
• Monitor: serum electrolytes (K⁺, Na⁺, Ca²⁺), urine output, blood pressure, weight — at least every 12 hours initially
• Discontinue and switch to furosemide as soon as it becomes available

---

Primary Indications — Paediatric (All OFF-LABEL)

---

1. Oedema Associated with Congestive Heart Failure — Paediatric

1. When to prefer over alternatives: No established advantage over furosemide in paediatric heart failure. Consider only when: (a) oral furosemide absorption is documented to be unreliable (e.g., gut oedema, malabsorption); (b) documented furosemide intolerance/allergy; © excessive rebound fluid retention with furosemide (theoretical — unproven in children). This makes it an alternative when furosemide is unsuitable, NOT a first-line choice. It is being compared against furosemide (first-line) and bumetanide (alternative — limited paediatric availability in India).
2. When NOT to use: Do not use in children <1 year (CYP2C9 immaturity). Do not use when IV diuretic is required (no IV torasemide in India). Do not use in haemodynamically unstable children requiring rapid diuresis (oral onset slower and unpredictable in children).
3. NLEM status: Not included in NLEM India for paediatric use.
4. Time to expected response: Onset of diuresis: 1–2 hours after oral dose (extrapolated from adult data); peak diuresis: 2–4 hours. If no increase in urine output within 4–6 hours of first dose, the dose is likely subtherapeutic.
5. Criteria for treatment failure: No increase in urine output or weight loss after 48–72 hours at the maximum dose for the child’s weight. Action: switch to IV furosemide if available; consider sequential nephron blockade with thiazide diuretic under specialist guidance.
6. Baseline investigations (MANDATORY): Serum electrolytes (K⁺, Na⁺, Mg²⁺, Ca²⁺), serum creatinine, blood urea, weight, blood pressure. RECOMMENDED: Echocardiography to guide volume status.
7. Specialist initiation: ⚠️ Specialist initiation recommended — paediatric cardiologist. Not for primary care prescribing in children.
8. Indian guideline source: Not included in IAP or MoHFW paediatric treatment guidelines. Furosemide dosing referenced in IAP Textbook of Pediatrics (current edition).
9. Key safety warning: ⚠️ Risk of excessive diuresis and hypovolaemia in children with already compromised cardiac output. Over-diuresis can precipitate low cardiac output state. Monitor weight loss — do not target >1–2% body weight loss per day in children.
10. Common dose adjustment scenarios: If concurrent potassium-losing state (diarrhoea, vomiting), hold diuretic and correct electrolytes before resumption. If concomitant digoxin therapy, maintain serum K⁺ ≥4.0 mEq/L.
11. Investigation misconception: Not applicable for this indication.
12. Dose escalation rationale: Not typically applicable in paediatric HF — doses are modest. If dose escalation is needed beyond 0.4 mg/kg/day, reconsider whether the child needs IV diuretics rather than further oral dose escalation.

---

2. Oedema Associated with Nephrotic Syndrome — Paediatric

1. When to prefer over alternatives: No established advantage over furosemide in paediatric nephrotic syndrome. In practice, furosemide remains preferred because: (a) IV furosemide + IV albumin (0.5–1 g/kg over 2–4 hours, followed by IV furosemide 1–2 mg/kg) is the standard for severe symptomatic oedema per IAP guidelines; (b) torasemide has no IV formulation in India. Torasemide may be an acceptable alternative for chronic oral maintenance diuresis in children with relapsing/frequently relapsing nephrotic syndrome where oral furosemide response is suboptimal or erratic.
2. When NOT to use: Do not use for initial management of severe anasarca/respiratory distress from nephrotic syndrome — IV albumin + IV furosemide is preferred. Do not use in children <1 year. Do not use if reliable oral intake is compromised (e.g., vomiting, gut oedema).
3. NLEM status: Not listed.
4. Time to expected response: Diuresis onset: 1–2 hours. In nephrotic syndrome, diuretic response is blunted (see below) — clinical response may take 24–48 hours to become apparent as meaningful weight loss.
5. Criteria for treatment failure: <0.5 kg weight loss per day after 72 hours at maximal dose. Action: (a) assess dietary sodium compliance; (b) switch to IV furosemide + IV albumin; © consider sequential nephron blockade with metolazone or hydrochlorothiazide.
6. Baseline investigations (MANDATORY): Serum electrolytes, serum creatinine, serum albumin, urinalysis (proteinuria quantification), weight. RECOMMENDED: Serum albumin guides whether albumin co-infusion is needed before diuretic (albumin <1.5 g/dL: consider IV albumin first).
7. Specialist initiation: Paediatric nephrologist.
8. Indian guideline source: IAP revised guidelines on management of steroid-sensitive nephrotic syndrome (Indian Pediatrics, 2021) recommend furosemide for oedema management. Torasemide is not specifically mentioned.
9. Key safety warning: ⚠️ In nephrotic syndrome, aggressive diuresis without adequate albumin can precipitate intravascular volume depletion and acute kidney injury, even though the child appears oedematous. Monitor serum albumin and intravascular volume status clinically (capillary refill, heart rate, blood pressure).
10. Common dose adjustment scenarios: Higher mg/kg doses may be needed compared to heart failure because of:
    • Intratubular albumin binding: Filtered albumin in the tubular lumen binds torasemide, reducing the free drug available to inhibit NKCC2
    • Reduced renal blood flow in hypovolaemic nephrotic state → less drug delivered to the tubule
    • Compensatory distal sodium reabsorption activated by ENaC upregulation
11. Investigation misconception: ℹ️ Serum drug levels of torasemide are NOT clinically useful and should NOT be ordered. The therapeutic target is urinary drug concentration at the tubular site of action, which cannot be measured clinically.
12. Dose escalation rationale: If dose escalation is needed, it is for efficacy (overcoming reduced tubular drug delivery and intratubular binding), not for safety. The systemically higher drug levels at these doses are tolerated because torasemide is hepatically cleared.

---

3. Oedema Associated with Chronic Kidney Disease — Paediatric

1. When to prefer over alternatives: In paediatric CKD, torasemide’s advantage of more predictable oral bioavailability (~80% vs furosemide’s variable ~40–60%) is theoretically relevant for chronic oral diuretic therapy. However, this advantage remains unproven in paediatric CKD populations. Furosemide is preferred due to IV availability and established paediatric dosing. Torasemide is an acceptable alternative ONLY under paediatric nephrologist supervision when oral furosemide response is documented as inconsistent.
2. When NOT to use: Acute fluid overload requiring urgent IV diuresis. Children <1 year. Anuric children (diuretics are ineffective in absent renal function).
3. NLEM status: Not listed for paediatric CKD.
4. Time to expected response: Onset 1–2 hours; response may be significantly attenuated in advanced CKD (eGFR <30 mL/min/1.73 m²).
5. Criteria for treatment failure: Inadequate weight loss or persistent oedema after 72 hours at maximum dose. Action: (a) verify sodium restriction compliance; (b) add metolazone 0.1–0.2 mg/kg (specialist only); © consider ultrafiltration/dialysis initiation.
6. Baseline investigations (MANDATORY): Serum electrolytes, serum creatinine, eGFR (Schwartz formula for paediatric GFR estimation), weight.
7. Specialist initiation: Paediatric nephrologist only.
8. Indian guideline source: No specific Indian paediatric guideline addresses torasemide use in paediatric CKD. IPNA clinical practice recommendations (2021) recommend loop diuretics for oedema in paediatric CKD without specifying agent preference.
9. Key safety warning: ⚠️ In paediatric CKD, aggressive diuresis can accelerate decline in residual renal function. Target gradual decongestion (0.5–1% body weight loss per day). Monitor serum creatinine closely — a rise of >0.3 mg/dL during active diuresis warrants dose reassessment.
10. Common dose adjustment scenarios: Higher mg/kg doses needed in advanced CKD (same principle as adults — reduced OAT-mediated tubular secretion). See Dose Escalation Rationale below.
11. Investigation misconception: Not applicable.
12. Dose escalation rationale: In paediatric CKD, dose escalation is for efficacy (overcoming impaired tubular drug delivery due to competing uraemic anions, reduced renal blood flow, and fewer functioning nephrons). The drug does not accumulate to systemically toxic levels because it is predominantly hepatically cleared. ⚠️ Do not reflexively reduce the dose in a child with CKD — if diuresis is inadequate, escalate the dose (up to the ceiling for the child’s weight and CKD stage) before concluding the drug has failed.

---

Secondary Indications — Paediatric (Off-label)

• The antihypertensive indication (low-dose torasemide 2.5–5 mg) has no paediatric data whatsoever. Loop diuretics are not first-line antihypertensives in children. If a diuretic is needed for paediatric hypertension, thiazide/thiazide-like diuretics (hydrochlorothiazide 0.5–1 mg/kg/day, chlorthalidone 0.3 mg/kg/day, amlodipine as non-diuretic first-line) are preferred per IAP and Indian paediatric nephrology practice.
• No paediatric data exists for torasemide use in hepatic oedema/ascites. In children with cirrhotic ascites, spironolactone (1–3 mg/kg/day) ± furosemide is the standard approach.

---

---

RENAL ADJUSTMENT

---

eGFR Formula Specification

---

Dose Escalation Framing — Efficacy vs Safety

• Torasemide clearance is ~80% hepatic (via CYP2C9) → systemic elimination is largely preserved in CKD
• Half-life increases modestly (from ~3.5 h to ~5–8 h in severe CKD/ESRD), unlike furosemide (where renal clearance is the dominant elimination pathway and half-life can increase dramatically)
• The modest half-life prolongation actually benefits diuretic efficacy by extending the duration of adequate luminal concentrations

• Ototoxicity risk increases at very high single-bolus doses (particularly relevant for IV furosemide; less data for oral torasemide, but caution applies above 100 mg single dose)
• Electrolyte disturbances (hypokalaemia, hyponatraemia, hypomagnesaemia) are dose-related and require monitoring — but these also occur at equivalent diuretic doses in patients with normal renal function
• Hypokalaemia risk may paradoxically be lower in advanced CKD (stages 4–5) because potassium excretion is already impaired; hyperkalaemia from CKD may partially offset diuretic-induced potassium loss
• Over-diuresis leading to pre-renal AKI is the most clinically relevant safety concern — monitor daily weight and do not target excessive fluid removal.

---

Renal Adjustment Table — Torasemide for Oedema (Heart Failure, Renal Disease, Nephrotic Syndrome, Hepatic Oedema)

---

Renal Adjustment Table — Torasemide for Hypertension (Low-Dose Indication)

---

Condition-Specific Renal Dosing Notes

• This is the most common clinical scenario requiring dose escalation
• Reduced cardiac output → reduced renal perfusion → diuretic resistance
• The “rightward shift” in dose-response is due to BOTH cardiac and renal factors
• Target weight loss: 0.5–1 kg/day. Do not target more aggressive diuresis even if high doses are used
• See Diuretic Resistance Management Protocol in Part 2 if ceiling dose is inadequate

• Additional diuretic resistance mechanism: filtered albumin in the tubular lumen binds torasemide, reducing the free drug available to act on NKCC2
• Some experts advocate co-administering IV albumin (25% albumin, 0.5–1 g/kg over 30 min) followed by the diuretic to “ferry” the drug to the kidney and reduce intraluminal binding — evidence is debated (meta-analyses inconclusive)
• Higher doses may be needed compared to heart failure at the same level of renal impairment

• See Hepatic Adjustment section below for the added complexity of hepatic metabolism impairment
• In hepatorenal syndrome: diuretics are generally ineffective and may worsen renal function. Discontinue diuretics if hepatorenal syndrome is suspected

---

Formulation-Specific Renal Adjustment

---

Augmented Renal Clearance (ARC)

• Torasemide is primarily hepatically cleared (~80%), so ARC has less impact on systemic drug clearance compared to predominantly renally-cleared drugs (aminoglycosides, vancomycin, meropenem).
• However, ARC may enhance the diuretic effect of torasemide because:
  • Increased renal blood flow → more drug delivered to peritubular capillaries
  • Enhanced OAT1/OAT3 activity → more efficient tubular secretion into the lumen
  • Result: standard doses may produce a more vigorous diuresis than expected

• No formal dose increase is required for ARC (unlike aminoglycosides/vancomycin where ARC mandates dose escalation to maintain therapeutic systemic levels)
• In young ICU patients with ARC, monitor closely for excessive diuresis and electrolyte depletion at standard doses
• If the clinical intent is aggressive decongestion (e.g., decompensated heart failure in a young patient), the enhanced renal delivery in ARC is therapeutically advantageous
• If the patient is euvolaemic and torasemide is being used for hypertension, consider the possibility of excessive diuresis and start at the lower end of the dose range

---

---

HEPATIC ADJUSTMENT

---

Overview

---

The Cirrhosis Paradox — Pharmacokinetic-Pharmacodynamic Dissociation

• Reduced CYP2C9 activity → slower metabolism → higher plasma levels and longer half-life for any given dose
• Reduced first-pass metabolism → higher oral bioavailability → even more drug reaches systemic circulation
• In severe hypoalbuminaemia: decreased protein binding → higher free drug fraction → enhanced pharmacological activity per mg and increased risk of dose-related adverse effects

• Secondary hyperaldosteronism (the hallmark of cirrhotic ascites) drives avid distal sodium reabsorption via ENaC and Na/K-ATPase → this counteracts loop diuretic-induced natriuresis at the thick ascending limb
• Reduced effective renal blood flow (hepatorenal physiology, even before overt hepatorenal syndrome) → reduced drug delivery to the tubular lumen via OAT pathway
• Activation of sympathetic nervous system and RAAS → further sodium and water retention
• Post-diuretic sodium rebound may be exaggerated in cirrhosis

---

Child-Pugh Classification-Based Adjustment

---

Formulation-Specific Hepatic Adjustment

---

CYP2C9 Polymorphism Interaction with Hepatic Impairment

---

Concurrent Hepatotoxin Note

---

Additional Hepatic Adjustment Notes

• Torasemide is >99% protein-bound. In severe hypoalbuminaemia (serum albumin <2.5 g/dL, common in Child-Pugh C cirrhosis), the free (unbound) fraction increases, potentially amplifying both therapeutic and toxic effects.
• However, in clinical practice, the increased free fraction often leads to more rapid distribution and elimination of the drug, partially compensating for the increased free concentration at the receptor level.
• Clinical translation: In severe hypoalbuminaemia, the drug may work faster but shorter. If duration of diuresis is inadequate, consider twice-daily dosing (e.g., 5 mg BD instead of 10 mg OD) rather than increasing the single dose.
• See Population PK — Hypoalbuminaemia in Part 1 for cross-cutting PK analysis.

• If torasemide clearance is severely impaired and dose titration becomes unpredictable: consider switching to furosemide, which is ~60–70% renally cleared and less dependent on hepatic CYP metabolism.
• However, this introduces furosemide’s own disadvantage: variable oral bioavailability (~40–60% vs torasemide’s ~80%), which may worsen in patients with gut oedema.
• Clinical decision: In Child-Pugh C with unstable hepatic function, IV furosemide (if inpatient) provides the most predictable pharmacokinetics. If outpatient oral therapy is needed, low-dose oral torasemide (5 mg OD, IR) with close monitoring may still be preferable to oral furosemide due to more reliable absorption.

• ⛔ If hepatorenal syndrome type 1 (rapidly progressive) is diagnosed or suspected: discontinue all diuretics (including torasemide and spironolactone). Diuretics are ineffective in HRS and may worsen renal hypoperfusion.
• Definitive management: terlipressin + albumin (per Indian guidelines — API Textbook of Medicine; INASL guidelines).
• In HRS type 2 (slowly progressive): diuretics may be cautiously continued at low doses if there is documented response (urine output, weight change), but with very close monitoring.

---

CONTRAINDICATIONS

---

Sulfonamide Cross-Reactivity — Structured Assessment

---

CAUTIONS

⚠️ High-Priority Cautions

---

---

• Loop diuretics in cirrhosis must be used with extreme caution. Aggressive diuresis can precipitate:
  • Hepatorenal syndrome (via intravascular volume depletion in the setting of systemic vasodilation)
  • Hepatic encephalopathy (via hypokalaemia and metabolic alkalosis)
  • Severe hyponatraemia (dilutional, worsened by impaired free water excretion)
• Target weight loss: ≤ 0.5 kg/day in patients with ascites ONLY; ≤ 1.0 kg/day in patients with BOTH ascites AND peripheral oedema
• Torasemide is typically used as second-line after spironolactone in cirrhotic ascites (spironolactone:torasemide ratio analogous to the standard spironolactone:furosemide 100 mg:40 mg ratio used in practice)
• Monitor serum electrolytes (K⁺, Na⁺), renal function, and encephalopathy grade at least twice weekly during active titration
• ⛔ HOLD diuretic if: Na⁺ < 125 mEq/L, K⁺ < 3.0 mEq/L, creatinine rises > 0.5 mg/dL above baseline, or encephalopathy worsens to ≥ grade II

• Hypokalaemia and hypomagnesaemia from torasemide significantly increase the risk of digitalis toxicity (nausea, visual disturbance, arrhythmias including fatal ventricular tachycardia/fibrillation)
• Maintain K⁺ ≥ 4.0 mEq/L and Mg²⁺ ≥ 2.0 mg/dL in all patients receiving concurrent digoxin
• Monitor digoxin levels more frequently during torasemide dose changes
• Consider adding spironolactone/eplerenone (which have potassium-sparing AND anti-aldosterone benefit in HF) to mitigate risk

• Torasemide may worsen glycaemic control via hypokalaemia-mediated impairment of insulin secretion
• Effect is generally modest and dose-dependent
• Monitor fasting blood glucose and HbA1c; may need to adjust antidiabetic medication
• At equinatriuretic doses, torasemide may cause less glucose intolerance than furosemide (limited data)

• Hyperuricaemia is dose-dependent and occurs in 40–60% of patients on chronic loop diuretics
• Patients with history of gout are at high risk of acute flares during diuretic initiation or dose escalation
• Prophylactic use of allopurinol/febuxostat may be considered in high-risk patients requiring chronic loop diuretic therapy
• An acute gout flare is NOT a reason to discontinue the diuretic if the original indication (e.g., decompensated HF) is still present — treat the gout flare while continuing the diuretic

• The concurrent use of ALL THREE drug classes produces a synergistic increase in AKI risk
  • NSAID: reduces prostaglandin-mediated afferent arteriolar vasodilation
  • ACEi/ARB: reduces angiotensin II–mediated efferent arteriolar vasoconstriction
  • Diuretic: reduces intravascular volume
• Combined effect: precipitous fall in GFR → AKI (Lapi F, BMJ 2013: 31% increased AKI risk with triple therapy)
• ⚠️ This scenario is EXTREMELY common in Indian practice because NSAIDs are widely available OTC and patients may self-medicate without informing the prescriber
• Action: Actively ASK about NSAID use (including “pain tablets,” “body pain medicine”) at every visit. If triple combination is unavoidable for a short period, ensure adequate hydration and monitor creatinine within 48–72 hours

• Hypokalaemia and hypomagnesaemia from torasemide can prolong QTc interval and predispose to torsades de pointes
• Risk is amplified when combined with other QT-prolonging drugs (amiodarone, sotalol, fluoroquinolones, antipsychotics, ondansetron at high doses, domperidone)
• Obtain baseline ECG; maintain K⁺ ≥ 4.0 mEq/L and Mg²⁺ ≥ 2.0 mg/dL
• Monitor ECG after any dose change or new QT-prolonging drug addition

---

Standard Cautions

---

PREGNANCY

---

LACTATION

---

ELDERLY

Deprescribing Guidance

---

MAJOR DRUG INTERACTIONS

Food-Drug and Herb-Drug Interactions (Major)

---

MODERATE DRUG INTERACTIONS

Food-Drug and Herb-Drug Interactions (Moderate)

---

COMMON ADVERSE EFFECTS

Very Common (≥ 10%)

Common (1–10%)

---

SERIOUS ADVERSE EFFECTS

⚠️ Ototoxicity — Loop Diuretic Class Effect

---

Other Serious Adverse Effects

Antidote / Overdose Management

---

LABORATORY TEST INTERFERENCE

---

MONITORING REQUIREMENTS

Electrolyte Monitoring Protocol (Diuretic-Specific)

---

Monitoring Timeline

• Monitor clinical signs of dehydration (skin turgor, mucous membranes, postural symptoms)
• Check BP lying and standing
• Weigh the patient (weighing scale is the single most valuable monitoring tool — ensure one is available)
• Ask about urine output pattern and colour
• If ANY clinical suspicion of renal impairment or electrolyte disturbance: refer to CHC/district hospital for labs before starting diuretic
• ⛔ Do NOT initiate high-dose torasemide (> 10 mg/day) without baseline electrolytes and creatinine

---

• If serum potassium cannot be checked: monitor for clinical signs of hypokalaemia — muscle weakness, cramps (especially calf cramps), fatigue, constipation, palpitations. If ECG is available, look for U waves, ST depression, T-wave flattening, and prolonged QTc.
• If serum sodium cannot be checked: monitor for confusion, drowsiness, nausea, headache, seizures (severe hyponatraemia).
• ⚠️ Counsel patients to report any of these symptoms immediately. These clinical surrogates are LESS reliable than laboratory monitoring — use them only when labs are genuinely unavailable, not as a substitute for standard care.

---

---

Volume Status Assessment Guidance

---

Therapeutic Drug Monitoring (TDM)

---

When to Stop Monitoring

• Electrolytes (K⁺, Na⁺) + creatinine: every 3 months
• Body weight: weekly (home monitoring by patient)
• BP (including orthostatic): every clinic visit
• Clinical volume assessment: every clinic visit

---

PATIENT COUNSELLING

---

---

• “Take this medicine BY MOUTH, usually ONCE a day.”
• “Take it in the MORNING — this is very important. If you take it too late in the day, you will need to use the toilet many times at night and your sleep will be disturbed.”
• “If you need a second dose, take it by 2–3 PM at the latest.”
• “You can take it with or without food — it works the same way. If it upsets your stomach, take it with a light snack.”
• “Swallow the tablet whole with a full glass of water.”

---

• “If you remember within 12 hours of your usual time, take the missed dose.”
• “If more than 12 hours have passed, SKIP the missed dose. Take the next dose at your usual time tomorrow morning.”
• “NEVER take two doses at the same time or double your dose to make up for a missed one.”
• “If you miss 3 or more doses in a row, do not restart on your own — call your doctor first. Your body may have held extra water, and your doctor may want to check you before restarting.”

---

• “You will pass urine MORE OFTEN than usual, especially in the first few days. This is expected — it means the medicine is working. This usually reduces after 1–2 weeks as your body adjusts.”
• “You may feel slightly dizzy or lightheaded when you stand up quickly. Get up slowly from a chair or bed. Sit on the edge of the bed for a few seconds before standing.”
• “You may experience mild headache, muscle cramps, or tiredness. These are usually temporary. Muscle cramps often improve if you eat potassium-rich foods (bananas, coconut water, oranges, dal).”

---

• ⚠️ “Severe dizziness, fainting, or feeling like you will fall”
• ⚠️ “Very fast or irregular heartbeat (palpitations)”
• ⚠️ “Severe muscle weakness — especially in your legs, making it hard to walk”
• ⚠️ “Confusion, severe drowsiness, or difficulty thinking clearly”
• ⚠️ “Very little or no urine output for more than 12 hours”
• ⚠️ “Ringing in your ears (tinnitus) or feeling that your hearing has changed”
• ⚠️ “Sudden joint pain and swelling (may be gout)”
• ⚠️ “Skin rash with blisters, peeling, or sores in the mouth”
• ⚠️ “Swelling of face, lips, or throat, or difficulty breathing (allergic reaction — go to emergency)”

---

• “AVOID taking pain medicines called NSAIDs (like ibuprofen, diclofenac, Combiflam, Voveran) without your doctor’s permission. These medicines can make your kidney function worse when combined with this medicine.”
• “LIMIT alcohol. Alcohol combined with this medicine can make your blood pressure drop too much and make you dizzy or faint.”
• “AVOID excessive licorice (mulethi) — it can work against this medicine and lower your potassium levels further.”
• “REDUCE SALT in your diet. Your doctor will tell you how much salt you can have — usually less than one teaspoon (5 grams) of table salt per day. This medicine works best when you also eat less salt.”
• “Do NOT use salt substitutes containing potassium (such as ‘lo-salt’) without asking your doctor — your potassium levels need to be monitored.”

---

• “Store at room temperature (below 30°C) in a cool, dry place.”
• “Keep away from direct sunlight and moisture.”
• “During hot Indian summers: do NOT store in a car, near a window with direct sun exposure, or in the kitchen near a stove. Keep in the coolest room of the house, inside a cupboard.”
• “Keep out of reach of children.”
• “No refrigeration needed.”

---

• “This medicine is usually taken for a LONG TIME — sometimes for life, especially if you have heart failure.”
• ⛔ “Do NOT stop taking this medicine suddenly because you feel better. Your body may hold extra water again, and your condition may worsen. Always ask your doctor before stopping.”
• “If you want to reduce or stop this medicine, your doctor will do it gradually.”

---

• “Your doctor will order BLOOD TESTS regularly — this is to check your kidney function and the levels of important minerals (potassium, sodium, magnesium) in your blood. These tests are very important — do NOT skip them.”
• “Weigh yourself EVERY MORNING — same time, after using the toilet, before eating, wearing similar clothes. Write down the number. If your weight goes up by more than 1.5 kg in 2 days, call your doctor.”
• “Bring your weight diary to every clinic visit.”

---

Common Patient Questions

---

Fasting Period Guidance

---

Caregiver/Family Counselling

• Daily weight monitoring: Teach the caregiver how to weigh the patient correctly (same time, same conditions) and when to contact the doctor (weight gain > 1.5 kg in 2 days, or any sudden increase in breathlessness or swelling).
• Recognising over-diuresis: Teach to look for: excessive thirst, dizziness on standing, dry mouth, sunken eyes, very dark or very little urine, confusion (especially in elderly patients — may be mistaken for “dementia”).
• Recognising under-diuresis / worsening congestion: Increasing ankle swelling, belly getting larger (ascites), difficulty breathing when lying flat, waking at night short of breath, weight gain.
• Medication adherence: Ensure the patient takes the medicine in the MORNING. If the caregiver prepares medications, label the pill box clearly.
• Elderly patients with cognitive impairment: The caregiver must supervise medication intake, daily weighing, and clinic visits. Keep a written record of daily weight, doses taken, and any symptoms.
• Toilet access: Ensure the patient has easy and SAFE access to a toilet — especially elderly patients who are at fall risk. Consider a bedside commode if the toilet is far from the bedroom.

---

India-Specific Adherence Support

---

BRANDS AVAILABLE IN INDIA

Jan Aushadhi / PMBJP Brands

---

Private / Commonly Available Brands

---

Fixed-Dose Combinations (FDCs)

---

---

PRICE RANGE (INR)

Single-Ingredient Torasemide — Per-Unit Pricing

NPPA / NLEM Status

Per-Month Cost at Usual Maintenance Dose

Comparative Cost Context — Loop Diuretics (Same Primary Indications)

FDC Pricing

---

CLINICAL PEARLS

---

---

---

---

---

1. Medication adherence — is the patient actually taking the medicine daily?
2. Dietary sodium intake — ask specifically about papad, pickles, processed foods, namkeen snacks, restaurant food, and added salt. Many Indian patients dramatically underestimate their sodium intake. A single serving of mango pickle can contain 1,500–2,000 mg sodium.
3. Concurrent NSAID use — ask about “pain tablets” and “body pain medicine.” Self-medication with diclofenac/ibuprofen is extremely common and can reduce diuretic response by 20–50%.

---

VERSION

---

REFERENCES

1. CDSCO Product Insert — Dytor (Torasemide) Tablets and Injection. Cipla Ltd. Most recent revision available as of 2024. [Used for: approved indications, contraindications, formulation verification, adverse effects, pregnancy/lactation labelling.]
2. Indian Pharmacopoeia 2022 (IP 2022). Indian Pharmacopoeia Commission, Ghaziabad. [Used for: drug identity, pharmacopoeial classification. Note: Torasemide monograph available but less detailed than CDSCO product insert.]
3. National List of Essential Medicines (NLEM), India, 2022. Ministry of Health & Family Welfare, Government of India. [Used for: confirming that torasemide is NOT listed; furosemide is the listed loop diuretic.]
4. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Brunton LL, Knollmann BC (eds). Chapter 25: Diuretics. McGraw-Hill. Pages relevant to loop diuretic pharmacology, NKCC2 mechanism, dose-response principles, ceiling dose concept, renal transporter pathways (OAT1, OAT3, MRP4), pharmacokinetics of torasemide, CYP2C9 metabolism, M1/M3/M5 metabolites, anti-aldosterone activity. [Primary pharmacology reference.]
5. Harrison’s Principles of Internal Medicine, 21st Edition (2022). Loscalzo J, Fauci AS, Kasper DL, et al. (eds). Chapter on Heart Failure Management (Chapter 257); Chapter on Cirrhotic Ascites Management; Chapter on Edema (Chapter 40). McGraw-Hill. [Used for: clinical context, disease-based dosing, diuretic resistance management.]
6. API Textbook of Medicine, 11th Edition (2019). Shah SN, Anand MP, Acharya VN, et al. (eds). Association of Physicians of India. Chapters on Heart Failure, Cirrhosis of the Liver, Chronic Kidney Disease, Hypertension. [Used for: Indian clinical practice context, first-line drug selection in Indian settings.]
7. Indian Guidelines on Hypertension — IV (IGH-IV, 2019). Hypertension India (Indian Society of Hypertension). Journal of the Association of Physicians of India (JAPI). [Used for: hypertension indication, BP targets, drug selection positioning.]
8. TRANSFORM-HF Trial. Mentz RJ, Anstrom KJ, Engelman ZJ, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023;329(3):214–223. doi:10.1001/jama.2022.23924. (n = 2,859; primary endpoint: all-cause mortality at 12 months; no significant difference HR 1.02, 95% CI 0.89–1.18.) [Used for: mortality equivalence between torasemide and furosemide, Clinical Pearls, Myth vs Fact.]
9. TORIC Study (observational). Cosin J, Diez J, TORIC Investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4(4):507–513. [Used for: historical context of torasemide vs furosemide comparison. Noted as observational/non-randomised with limitations.]
10. Brater DC. Pharmacology of Diuretics. American Journal of Medical Sciences. 2000;319(1):38–50. [Used for: dose-response principles, ceiling dose concept, bioavailability comparison between loop diuretics.]
11. Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57(6):601–609. [Used for: bioavailability comparison, absorption in HF patients.]
12. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998;45(6):525–538. [Used for: CYP2C9 metabolism of torasemide, metabolite identification, pharmacogenomic context.]
13. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349(17):1628–1635. [Used for: sulfonamide cross-reactivity table.]
14. Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525. [Used for: “triple whammy” interaction data.]
15. Testani JM, Coca SG, McCauley BD, et al. Impact of changes in blood pressure during the treatment of acute decompensated heart failure on renal and clinical outcomes. Eur J Heart Fail. 2011;13(8):877–884. [Used for: pseudo-WRF vs true AKI distinction.]
16. DOSE Trial. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805. [Used for: IV dosing strategies, bolus vs infusion, high-dose vs low-dose context.]
17. LactMed (NIH Drugs and Lactation Database). National Library of Medicine, Bethesda MD. Torasemide entry and Furosemide entry. [Used for: lactation safety data, furosemide as preferred alternative in breastfeeding.]
18. 1mg.com, PharmEasy.in — online Indian pharmacy platforms. [Used for: brand availability verification, current pricing data, FDC composition verification. Accessed June–July 2025.]
19. ICMR Antimicrobial Resistance Surveillance data. Not directly used (not relevant to diuretics), but cited methodology is analogous to ICMR approach for Indian-specific practice data.
20. IAP Drug Formulary / Nelson Textbook of Pediatrics, 21st Edition (2020). Kliegman RM et al. (eds). Elsevier. [Used for: paediatric dosing context, minimum age/weight limits, paediatric PK notes.]

---